Skip to main content
    P

    Pacira BioSciences, Inc. (PCRX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $36.48
    +0.02 (+0.05%)

    Market Cap: $1.46B

    Last updated: Nov 17, 2026 at 3:04 AM ET

    Pacira BioSciences, Inc. (PCRX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Pacira BioSciences reported revenue of $726.41M for the fiscal year ended Dec 31, 2025, up 3.6% from the year before. That year, net income was $7.03M with a net margin of 1.0%, operating cash flow was $151.99M and free cash flow was $136.66M. The quarter ended Sep 30, 2026 had revenue of $176.65M and net income of $28.52M.

    Revenue and Margins

    The operating margin was 2.6% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $276.37M, a compound annual rate of 11.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$726.41M+3.6%79.4%2.6%1.0%
    Dec 2024$700.97M+3.9%75.7%-10.5%-14.2%
    Dec 2023$674.98M-49.4%72.6%13.0%6.2%
    Dec 2022$1.33B+146.3%85.1%4.5%2.4%
    Dec 2021$541.53M+26.0%74.1%16.6%7.8%
    Dec 2020$429.65M+2.0%72.7%10.8%33.9%
    Dec 2019$421.03M+24.8%74.7%2.5%-2.6%
    Dec 2018$337.28M+17.7%74.3%4.7%-0.1%
    Dec 2017$286.63M+3.7%69.3%-8.7%-14.9%
    Dec 2016$276.37MN/A60.2%-11.6%-13.7%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income rose 425.2% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$726.41M$700.97M$674.98M$1.33B$541.53M$429.65M$421.03M$337.28M$286.63M$276.37M
    Cost of revenue$149.75M$170.43M$184.67M$199.29M$140.25M$117.33M$106.71M$86.84M$87.92M$110.10M
    Gross profit$576.66M$530.54M$490.31M$1.13B$401.28M$312.32M$314.31M$250.43M$198.72M$166.27M
    Research and development$117.31M$81.58M$76.26M$84.80M$55.55M$59.42M$72.12M$55.69M$57.29M$45.68M
    Operating income$19.19M-$73.37M$87.67M$60.02M$89.92M$46.35M$10.48M$15.91M-$24.94M-$32.02M
    Net income$7.03M-$99.56M$41.95M$31.82M$41.98M$145.52M-$11.02M-$471.00K-$42.61M-$37.95M
    EBITDA$101.66M$842.00K$162.24M$100.72M$141.71M$87.36M$40.53M$40.99M$734.00K-$14.62M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$176.65M$192.40M$177.38M$196.87M$179.52M$181.10M$168.92M$187.25M$168.57M$178.02M$167.12M$181.24M
    Gross profit$139.42M$148.24M$140.96M$156.57M$145.24M$140.23M$134.62M$147.37M$129.71M$133.76M$119.70M$133.55M
    Operating income$22.27M$4.27M$6.90M$2.34M$6.36M$8.50M$1.99M$24.70M-$139.53M$28.24M$13.21M$33.17M
    Net income$28.52M$4.65M$2.92M$1.64M$5.43M-$4.85M$4.81M$16.04M-$143.47M$18.89M$8.98M$24.87M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $382.03M exceeded cash and equivalents by $223.48M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$1.26B$1.55B$1.57B$1.68B$2.08B$1.27B$831.07M$689.35M$628.37M$391.47M
    Current assets$547.97M$745.13M$509.99M$498.33M$866.05M$651.62M$408.56M$477.97M$391.11M$243.09M
    Cash and equivalents$158.54M$276.77M$153.30M$104.14M$585.58M$99.96M$78.23M$132.53M$54.13M$35.94M
    Total liabilities$571.81M$775.17M$704.26M$906.19M$1.34B$654.83M$476.12M$368.13M$348.89M$172.49M
    Short-term debt$9.84M$201.78M$8.64M$33.65M$374.70M$149.65M$0$338.00K$324.00K$0
    Long-term debt$372.19M$383.55M$513.80M$655.82M$674.53M$313.03M$306.05M$290.59M$276.17M$108.74M
    Shareholder equity$693.11M$778.35M$870.13M$775.01M$730.41M$619.69M$354.94M$321.23M$279.48M$218.98M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.20B$1.24B$1.21B$1.26B$1.30B$1.54B$1.59B$1.55B$1.52B$1.65B$1.58B$1.57B
    Total liabilities$490.32M$572.00M$554.64M$571.81M$570.36M$779.50M$788.13M$775.17M$772.11M$767.54M$691.16M$704.26M
    Cash and equivalents$246.96M$205.88M$144.31M$158.54M$147.59M$300.48M$283.61M$276.77M$245.97M$247.05M$184.05M$153.30M
    Shareholder equity$712.32M$671.98M$653.89M$693.11M$727.21M$757.77M$798.54M$778.35M$749.58M$879.28M$892.16M$870.13M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 89.9% of operating cash flow. Share repurchases came to 110.1% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$151.99M$189.39M$154.65M$145.27M$125.72M$77.03M$70.52M$48.87M$17.79M$33.45M
    Capital expenditures$15.33M$10.64M$15.16M$30.08M$45.87M$37.80M$10.16M$14.51M$19.27M$24.71M
    Free cash flow$136.66M$178.75M$139.49M$115.20M$79.85M$39.23M$60.36M$34.36M-$1.48M$8.74M
    Dividends paidN/AN/A$2.81MN/A$2.67M$1.62M$4.32MN/A$0$0
    Share repurchases$150.51M$34.35M$1.16M$1.18M$4.55MN/AN/AN/AN/AN/A
    Investing cash flow$99.48M-$83.28M$77.54M-$225.19M-$20.79M-$277.61M-$128.49M$20.58M-$223.76M-$61.75M
    Financing cash flow-$369.63M$17.36M-$183.03M-$401.53M$380.69M$222.30M$3.67M$8.95M$224.16M$7.26M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$50.07M$57.46M$25.68M$43.69M$60.83M$12.01M$35.46M$33.13M$53.92M$53.24M$49.10M$47.58M
    Capital expenditures$3.63M$1.34M$2.72M$218.00K$3.87M$2.70M$8.55M$2.12M$4.09M$1.59M$2.84M$1.80M
    Free cash flow$46.45M$56.12M$22.96M$43.47M$56.96M$9.31M$26.91M$31.01M$49.83M$51.65M$46.27M$45.79M
    Last 12 quarters

    Frequently Asked Questions About PCRX

    What is Pacira BioSciences' annual revenue?

    Pacira BioSciences reported revenue of $726.41M for the fiscal year ended Dec 31, 2025.

    How fast is Pacira BioSciences' revenue growing?

    Revenue was up 3.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -18.3%.

    Is Pacira BioSciences profitable?

    Yes. Pacira BioSciences reported net income of $7.03M for the fiscal year ended Dec 31, 2025, with a net margin of 1.0%.

    How much free cash flow does PCRX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $151.99M minus capital expenditures of $15.33M produced free cash flow of $136.66M.

    How much debt does Pacira BioSciences have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $372.19M, short-term debt of $9.84M and cash and equivalents of $158.54M.